1-3 of 3
Thelma Angeles
Close
Sort by
Journal Articles

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Elizabeth O. Hexner, Cynthia Serdikoff, Mahfuza Jan, Cezary R. Swider, Candy Robinson, Shi Yang, Thelma Angeles, Stephen G. Emerson, Martin Carroll, Bruce Ruggeri, Pawel Dobrzanski
Journal: Blood
Blood (2008) 111 (12): 5663–5671.
https://doi.org/10.1182/blood-2007-04-083402
Published: 2008
Includes: Supplemental data
Journal Articles

CEP-701 Is a JAK2 Inhibitor Which Attenuates JAK2/STAT5 Signaling Pathway and the Proliferation of Primary Cells from Patients with Myeloproliferative Disorders.

Pawel Dobrzanski, PhD, Elizabeth Hexner, MD, Cynthia Serdikoff, Mahfuza Jan, Cezary Swider, PhD, Candy Robinson, Shi Yang, PhD, Thelma Angeles, PhD, Stephen G. Emerson, MD,PhD, Martin Carroll, MD, Bruce Ruggeri, PhD
Journal: Blood
Blood (2006) 108 (11): 3594.
https://doi.org/10.1182/blood.V108.11.3594.3594
Published: 2006
Journal Articles

Identification and Characterization of an ALK Inhibitor That Attenuates the Proliferation and Survival of Anaplastic Large Cell Lymphoma-Derived Cell Lines and ALK Dependent Cell Lines.

Mangeng Cheng, Ph.D., Weihua Wan, Mark Albom, Linda Weinberg, Thelma Angeles, Ph.D., Matthew Quail, Lihui Lu, Ted Underiner, Ph.D., Robert Hudkins, Ph.D., Mark Ator, Ph.D., Bruce Ruggeri, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2485.
https://doi.org/10.1182/blood.V104.11.2485.2485
Published: 2004